GLYCOPYRROLATE MSDS PDF

SAFETY DATA SHEET. PRODUCT: Glycopyrrolate Injection USP. Section 1: PRODUCT AND COMPANY INFORMATION. 54/1, Boodhihal village,. Nelamangala. Glycopyrrolate. 1-Methylpyrrolidyl alpha-phenylcyclopentaneglycolate methobromide;. Glycopyrrolate bromide; Glycopyrronium bromide. Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent In October , glycopyrrolate was approved by the FDA for use as a FDA label. Download ( KB). MSDS. Download ( KB).

Author: Faem Daishura
Country: Mexico
Language: English (Spanish)
Genre: Sex
Published (Last): 9 June 2011
Pages: 212
PDF File Size: 17.30 Mb
ePub File Size: 8.98 Mb
ISBN: 543-1-36801-754-1
Downloads: 93493
Price: Free* [*Free Regsitration Required]
Uploader: Doumi

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Cilostazol.

The hlycopyrrolate efficacy of Deacetylbisacodyl can be decreased when used in combination with Glycopyrronium. Ritodrine The risk or severity of Tachycardia can be increased when Ritodrine is combined with Glycopyrronium. GW The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with GW Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Glycopyrronium.

The serum msde of Methyclothiazide can be increased when it is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ipidacrine.

The risk or severity of adverse effects can be increased when Phenglutarimide is combined with Glycopyrronium. Hydrocodone The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydrocodone. The risk or severity of Tachycardia can be increased mdss Glycopyrronium is combined with Hexoprenaline.

The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Pirbuterol. Orciprenaline The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Glycopyrronium. Alphacetylmethadol The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Alphacetylmethadol. Talbutal Talbutal may increase the anticholinergic activities of Glycopyrronium.

Piritramide The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Piritramide. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ketamine. Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Glycopyrronium. Magnesium citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Glycopyrronium. The therapeutic efficacy of Potassium nitrate can be decreased when used in combination with Glycopyrronium.

  LA DOCTRINA SECRETA DE HELENA PETROVNA BLAVATSKY PDF

Ipidacrine The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ipidacrine.

Rilmenidine The risk or glycopyrrolafe of Tachycardia can be increased when Glycopyrronium is combined with Rilmenidine. Aprotinin The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Aprotinin. The risk or severity of Glycoopyrrolate can be increased when Isoetarine is combined with Glycopyrronium.

Aluminum sulfate The therapeutic efficacy of Aluminum sulfate can be decreased when used in combination with Glycopyrronium. Tetryzoline The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Tetryzoline.

Mefenorex The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Mefenorex. The serum concentration of Chlorthalidone can be increased when it is combined with Glycopyrronium. Nat Rev Drug Discov. Fesoterodine The risk or severity of adverse effects can be increased msdz Fesoterodine is combined with Glycopyrronium.

Acebutolol The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Acebutolol. The risk or severity of Tachycardia and drowsiness can be increased when Glycopyrronium is combined with Dronabinol.

Rapacuronium The risk or severity of adverse effects can be increased when Rapacuronium is combined with Glycopyrronium. The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Isoflurophate.

Cirazoline The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Cirazoline. Picosulfuric acid The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Glycopyrronium. Nicardipine The risk or severity of adverse glycopyrro,ate can be increased when Nicardipine is combined with Glycopyrronium.

Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Glycopyrronium. Nicomorphine The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Nicomorphine.

  ABNT NBR 10636 PDF

U Muscarinic acetylcholine receptor M3. Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glycopyrronium.

Glycopyrronium

Sodium fluorophosphate The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Glycopyrronium. The risk or severity of adverse effects can mzds increased when Glycopyrronium is combined with Levorphanol. The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Mefenorex. General Function Receptor activity Specific Function The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the The therapeutic efficacy of Magnesium Trisilicate can be decreased when used in combination with Glycopyrronium.

The risk or severity of Tachycardia can be increased when Methoxamine is combined with Glycopyrronium.

Glycopyrronium – DrugBank

The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with 1,Phenanthroline. Xylometazoline The risk or severity of Tachycardia can be increased when Glycopyrronium is combined with Xylometazoline. Bezitramide The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Bezitramide.

Epinephrine The risk or severity of Tachycardia can be increased when Epinephrine is glycopyrrllate with Glycopyrronium. Phenobarbital Glycopyrronium may increase the anticholinergic activities of Phenobarbital. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Nalbuphine. General Injectables and Vaccines Inc.

Doxylamine The risk or severity of adverse effects can be increased when Doxylamine is combined with Glycopyrronium. Phenolphthalein The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Glycopyrronium. Ambenonium The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Ambenonium.